Miller v. Comm'r
Opinion
MEMORANDUM OPINION
KROUPA,
The sole issue for decision is whether we lack jurisdiction to redetermine the deficiencies and penalties at issue because the deficiency notice is invalid. We hold that the notice is invalid because it adjusts affected items that cannot be litigated until the conclusion of the ongoing partnership-level proceeding. Accordingly, we shall grant respondent's motion.
The facts we recite are uncontested facts admitted in the petition, respondent's motion, petitioner's objection to respondent's motion, or the exhibits attached to these documents. Petitioner resided in Florida at the time she filed the petition.
Petitioner owned three million shares of Bristol-Myers Squibb stock (BMY stock) directly or indirectly through her wholly owned S corporation, Nevadamax, Inc. (Nevadamax). *185 Petitioner transferred her BMY stock to the partnership in exchange for a 99-percent limited partnership interest and a 0.6-percent general partnership interest. Nevadamax, in turn, transferred its BMY stock to the partnership for a 0.4-percent limited partnership interest. Petitioner formed the Miller CRAT four days later and contributed her 99-percent limited partnership interest to the Miller CRAT. Petitioner was the term beneficiary of the Miller CRAT and was entitled to monthly distributions (CRAT distributions) until the CRAT terminated in 2001.
The day after transferring her limited partnership interest to the Miller CRAT, petitioner caused the partnership and Bear Stearns International Ltd. (Bear Stearns) to enter into a variable forward purchase contract concerning the BMY stock. The confirmations of this agreement set forth the terms of the BMY stock sale including a "purchase date" of August 2001. Bear Stearns paid the partnership $ 198 million in 1999, however, under the agreement.
The partnership made cash distributions to the Miller CRAT during the years at issue. These distributions were calculated to meet the Miller CRAT's monthly distribution obligations to petitioner. *186 The primary source of these distributions was the $ 198 million payment from Bear Stearns. The Miller CRAT made CRAT distributions in excess of $ 204 million to petitioner from July 1999 through June 2001. Petitioner treated the CRAT distributions as nontaxable returns of corpus under
Respondent challenged petitioner's reporting position under two alternative theories. Respondent's first theory is presented in the FPAA. Respondent determined in the FPAA, among other things, that the partnership made a closed and completed sale of the BMY stock when it executed the variable prepaid forward contract and therefore had approximately $ 214 million in capital gain income for 1999 (partnership gain issue). Respondent determined the $ 214 million gain by subtracting the partnership's basis in the BMY stock from the consideration the partnership received from Bear Stearns ($ 198 million in cash plus the contingent right to future appreciation, according to respondent). Petitioner caused Nevadamax, the partnership's tax matters partner, to timely file a petition with this Court. The partnership-level case is pending at docket no. 16013-08.
Respondent's *187 second theory is included in the deficiency notice, in which respondent challenges petitioner's tax treatment of the CRAT distributions under
Petitioner timely filed a petition with this Court, and respondent filed a motion to dismiss for lack of jurisdiction before filing an answer. It is this motion that we address.
We must decide whether the deficiency notice is invalid because it adjusts affected items and was issued before the conclusion of the related partnership-level proceeding. We first discuss the tax treatment of distributions from charitable remainder annuity trusts generally. We then turn to respondent's treatment of the CRAT distributions in the deficiency notice. Finally, we examine respondent's determinations in the deficiency notice under the TEFRA partnership provisions to decide we do not have jurisdiction.
The tax treatment of distributions from a charitable remainder annuity trust to its beneficiary is determined under a four-tier system. See
Each year the trustee must completely distribute all of the historical value of income in one category before distributing any from the next category. The four-tier system causes a beneficiary to treat distributions from a charitable remainder annuity trust as being pulled first from sources with the highest income tax rate.
Tax planners began to look for ways around the four-tier system to avoid higher tax rates for their clients. The Secretary issued the CRAT anti-abuse regulation in January 2001 to address inappropriate manipulation of the four-tier system for tax avoidance. See
Respondent challenges petitioner's tax treatment of the CRAT distributions under the CRAT anti-abuse regulation. Respondent ultimately *190 concludes that the CRAT anti-abuse regulation applies and petitioner erroneously treated the CRAT distributions as return of corpus rather than capital gain for the years at issue. 3 The regulation applies only, however, to the extent that the CRAT distributions would otherwise be characterized in the hands of petitioner as distributions of trust corpus. See
With this understanding of respondent's determinations in the deficiency notice, we now turn to the jurisdictional issue in this case.
The Tax Court is a court of limited jurisdiction, and we may exercise our jurisdiction only to the extent provided by Congress. See
Petitioner argues that the deficiency notice is valid because it adjusts items that are unrelated to the determinations in the FPAA. Respondent counters that the deficiency notice is invalid because it adjusts items that depend on the outcome of the partnership gain issue in the partnership-level proceeding. We agree with respondent.
Partnership items are determined in partnership-level proceedings under TEFRA, while nonpartnership items are determined at the individual partner level.
Partnership-level determinations also impact certain items of individual partners. These are referred to as affected items, and their resolution depends on partnership-level determinations. See
We now turn to whether the adjustments in the deficiency notice are attributable to affected items that flow from the partnership gain issue so that we lack jurisdiction over them here. Petitioner argues that respondent's recharacterization of the CRAT distributions under the CRAT anti-abuse regulation and the related penalties are not affected items. 5*194 We disagree. Both items are in fact affected items that must await a determination of the partnership gain issue at the partnership level.
An affected item is any item to the extent such item is affected by a partnership item. See
In addition, respondent determined that petitioner is liable for accuracy-related penalties under
We conclude that respondent improperly issued the deficiency notice recharacterizing the CRAT distributions before the decision of this Court has become final in the ongoing partnership-level proceeding. Accordingly, we hold that the deficiency notice is invalid and there is no jurisdictional basis upon which this Court may consider the adjustments.
We have considered all the arguments of the parties, and, to the extent we have not addressed them, we find them to be irrelevant, moot, or meritless.
To reflect the foregoing,
Footnotes
1. All section references are to the Internal Revenue Code in effect for the years at issue, unless otherwise indicated.↩
2. The adjustments to itemized deductions are purely computational and depend on the primary adjustment to petitioner's capital gain income.↩
3. In doing so, respondent determined that the Miller CRAT's participation in the partnership is disregarded for purposes of determining the tax treatment of the distributions. Respondent therefore treated the Miller CRAT as having sold a pro rata portion of the BMY stock during the years at issue and recognizing capital gain to the extent the CRAT distributions exceeded the stock's allocable basis.↩
4. Partnership items include "The partnership aggregate and each partner's share of * * * Items of income, gain, loss, deduction or credit of the partnership."
sec. 301.6231(a)(3)-1(a)(1) , Proced. & Admin. Regs. Partnership items also include "the accounting practices and the legal and factual determinations that underlie the determination of the amount, timing, and characterization of items of income, credit, gain, loss, deduction, etc."Sec. 301.6231(a)(3)-1(b)↩ , Proced. & Admin. Regs.5. Although petitioner's argument is not entirely clear, she appears to contend that the operation of the CRAT anti-abuse regulation would be an affected item only if it had a bearing on the taxable amount of the CRAT distributions arising from the partnership gain issue. We reject this argument. An affected item is any item to the extent such item is affected by a partnership item. See
sec. 6231(a)(5)↩ . An affected item is not required to have an impact on any other item, however.6. The parties agree that the tax treatment of the CRAT distributions under
sec. 664(b)↩ is an affected item.7. This is true even if respondent is required to make computational adjustments only for any portion of the CRAT distributions properly characterized as capital gain income under
sec. 664(b)↩ .8. Petitioner argues that this proceeding provides her only opportunity to challenge the validity of the CRAT anti-abuse regulation. We disagree. The recharacterization of the CRAT distributions under the CRAT anti-abuse regulation requires various partner-level determinations, including, but not limited to, the values and bases of the Miller CRAT's assets. See
sec. 1.643(a)-8(b)(1) and(2), Income Tax Regs. ; see alsosec. 6230(a)(2)(A)(i) ; (partner-level determination under sec. 469 passive loss rules is an affected item), supplemented byEstate of Quick v. Commissioner , 110 T.C. 172, 181-182110 T.C. 440 (1998) ; (characterization of a guaranteed payment as a lump-sum payment underJenkins v. Commissioner , 102 T.C. 550, 556-557 (1994)sec. 104 is an affected item). Accordingly, petitioner may have the opportunity to challenge the regulation's validity, if necessary, in an affected items deficiency proceeding after the conclusion of the partnership-level proceeding.
Case-law data current through December 31, 2025. Source: CourtListener bulk data.